Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Inclusion Criteria: * Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level \<1 %) * \>/= 18 but \</= 65 years of age * Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days (as supported by the subject's medical history) * Immunocompetent with a CD4+ lymphocyte count \> 400/mm³ * Signed informed consent from subject Exclusion Criteria: * Documented history of inhibitor to Factor VIII with a titer \>/= 0.6 BU (Biological Unit), by the Nijmegen modified assay. However, subjects with a maximum historical titer of \</= 1.0 BU with the classical Bethesda assay on a single measurement but with at least 3 subsequent successive negative results (\< 0.6 BU) thereafter are eligible. * Unable to stop Factor VIII treatment to complete a minimum 72 hour washout * Current evidence of inhibitor to Factor VIII with a titer \>/= 0.6 BU, measured at the time of screening * Abnormal renal function (serum creatinine \> 1.5 times the upper limit of the normal range) * Total bilirubin \> 1.5 times the upper limit of the normal range * Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \> 2 times the upper limit of the normal range) * Any concomitant coagulation disorder other than hemophilia A (including lupus anticoagulant) * Platelet count \< 100,000/mm³ * Within the last 3 months prior to study entry or during the study will be treated with an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon, steroids, rituximab, etc) * Any subject who requires major surgery during study period. Minor procedures may be approved if discussed in advance with the medical expert.